Innate Pharma enters the second half of 2026 with a reshaped financial and development strategy centered on advancing its cancer-immunotherapy pipeline while transferring commercial responsibility for lacutamab to a larger partner. The completion of its strategic agreement with Sobi provides an immediate $75 million upfront payment, while a separate €30 million equity financing adds further capital for clinical development and the company’s antibody-drug conjugate portfolio.

As of June 30, Innate held €21.4 million in cash, cash equivalents, short-term investments and financial assets, compared with €44.8 million at the end of 2025. Despite the decline, management expects the Sobi payment and equity proceeds to extend its projected cash runway until the end of Q1 2028, giving the company greater visibility as several programs reach important clinical milestones.

Lacutamab Moves Into a More Advanced Development Stage

The Sobi transaction is particularly important because it enables the TELLOMAK-3 confirmatory Phase 3 trial for lacutamab in cutaneous T-cell lymphoma. The first patient is expected to enter the study in the first quarter of 2027, with the program targeting potential regulatory applications in Sézary syndrome and mycosis fungoides.

Under the agreement, Innate remains responsible for conducting the Phase 3 trial, while Sobi receives exclusive global commercialization rights following potential accelerated approval. Innate could also receive up to $40 million in near-term development milestones and as much as $465 million tied to development rights, regulatory and commercial milestones, in addition to tiered double-digit royalties on net sales.

IPH4502 Becomes a Central Growth Asset

While lacutamab provides a partnered late-stage opportunity, Innate is also concentrating resources on IPH4502, its Nectin-4 antibody-drug conjugate. The Phase 1 program completed dose escalation and cohort-enrichment enrollment in July, with 76 patients enrolled across several tumor types expressing Nectin-4.

Preliminary activity has been observed in heavily pretreated patients, including responses in urothelial cancer following prior treatment with enfortumab vedotin, as well as in non-small cell lung cancer and head and neck squamous cell carcinoma. Initial Phase 1 dose-escalation data are scheduled for presentation on November 18, 2026, creating an important upcoming catalyst for the company’s proprietary pipeline.

Additional Programs Add Clinical Optionality

Innate also continues to participate in the development of monalizumab with AstraZeneca. The PACIFIC-9 Phase 3 trial in unresectable Stage III non-small cell lung cancer has completed enrollment, with results expected in the second half of 2026. Meanwhile, the Phase 2 MATISSE study of IPH5201 continues enrollment in a defined PD-L1-positive patient population after encouraging interim results.

Financial discipline has also become more visible. Operating expenses fell to €24.7 million in the first half of 2026 from €30.3 million a year earlier, while research and development spending declined to €16.9 million. The company reported a net loss of €19.6 million, compared with €21.3 million in the first half of 2025.

What Investors Will Watch Next

Innate’s outlook will increasingly depend on clinical execution and the ability to convert partnerships and financing into progress across its pipeline. The Sobi transaction provides additional financial visibility, while IPH4502 and monalizumab offer separate potential catalysts before the end of the year.

The November IPH4502 data, the PACIFIC-9 readout and preparation for TELLOMAK-3 will therefore be key developments to monitor. Together, they will provide investors with additional evidence of how effectively Innate can balance partnered programs, proprietary drug development and capital discipline.